Alan Ezekowitz - 26 Jun 2025 Form 4 Insider Report for Fulcrum Therapeutics, Inc. (FULC)

Reporting relationship: Director
Issuer ticker: FULC
Reported as of: 26 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 Jun 2025, 16:15:04 UTC
Prior SEC filing: 20 Jun 2025
Next SEC filing: 15 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Greg Tourangeau, as attorney-in-fact for Alan Ezekowitz

Key filing fact

Alan Ezekowitz filed Form 4 for Fulcrum Therapeutics, Inc. (FULC) on 30 Jun 2025.

Key facts

This page summarizes Alan Ezekowitz's Form 4 filing for Fulcrum Therapeutics, Inc. (FULC).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 30 Jun 2025, 16:15.

Change

Previous filing in this sequence was filed on 20 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001780209 Primary reporting owner

Ezekowitz Alan

Relationship: Director
Address: C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE
Signature: /s/ Greg Tourangeau, as attorney-in-fact for Alan Ezekowitz
Signature date: 30 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FULC transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +36,000
Change %
Price: $0.000000
Shares after: 36,000
Date: 26 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 36,000
Exercise price: $7.38
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option was granted on June 26, 2025 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.